Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

Official title

Enhancing Prefrontal Oscillatory Activity and Working Memory Performance With Noninvasive Brain Stimulation in Early-course Schizophrenia

Overview

This study will investigate the effects of intermittent Theta Burst Stimulation (iTBS) on natural oscillatory frequency of the dorsolateral prefrontal cortex (DLPFC) and working memory in early-course schizophrenia (EC-SCZ). Transcranial magnetic stimulation (TMS) will be used to evoke oscillatory activity, and EEG will record the responses of EC-SCZ participants. A working memory task will also be incorporated in order to determine how DLPFC natural frequency (NF) is related to working memory performance. iTBS (active or sham) will be administered, then the oscillatory activity of DLPFC and working memory performance will be reassessed. The overarching goal is to determine whether iTBS can acutely enhance the oscillatory activity of the DLPFC and to evaluate the relationship between changes in the DLPFC and working memory performance.

Detailed description

The overarching goal of this proposal is to establish whether, by acutely enhancing dorsolateral prefrontal cortex (DLPFC) oscillatory deficits experimentally, there is a corresponding improvement in working memory (WM) function in early-course schizophrenia (EC-SCZ) patients. To achieve this goal, the investigators will perform TMS/EEG assessments of DLPFC and related oscillatory parameters and evaluate WM ability with the AX-Continuous Performance Task (AX-CPT) before and after two theta burst stimulation (TBS) sessions (intermittent (iTBS) and sham TBS of DLPFC) in 75 EC-SCZ patients.

Aim 1. Establish the acute effects of active vs. sham TBS on DLPFC oscillatory activity/NF of EC-SCZ patients. The investigators will iTBS to enhance DLPFC oscillatory activity/NF, as assessed with TMS/EEG, in EC-SCZ patients.

H1: TBS condition (active vs sham) will moderate the change in DLPFC oscillatory activity/NF from pre to post-TBS, such that DLPFC oscillatory activity/NF will increase following iTBS (but not sham).

Aim 2. Assess the impact of acute active vs. sham TBS on WM performance in EC-SCZ patients. The investigators will assess the acute impact of active vs. sham iTBS on WM performance in EC-SCZ patients.

H2: iTBS condition (active vs sham) will moderate the change in WM from pre- to post-TBS, such that AX-CPT performance will improve following iTBS (but not sham).

Aim 3. Examine the relationship between TBS-related changes in DLPFC oscillatory activity/NF and WM performance in EC-SCZ patients.

H3: iTBS-induced increase in DLPFC oscillatory activity/NF will predict better post-iTBS WM performance in EC-SCZ patients.

Interventions

• Device active intermittent Theta Burst Stimulation (iTBS)
  iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with patients with schizophrenia. This research study is using iTBS off label in SCZ patients to examine research questions.
• Device sham intermittent Theta Burst Stimulation (iTBS)
  Sham TBS over the left DLPFC will be performed using a Cool-B65 A/P TMS coil, designed to support blinded clinical trials. Specifically, when the coil is placed in the "P" position (i.e. the "placebo" position), only a very small amount of current is induced in tissue, thus preventing the activation of cortical neurons.

Primary outcome measures

• Change in dorsolateral prefrontal cortex natural frequency (DLPFC NF) following iTBS [Time frame: baseline (pre iTBS), within one hour from iTBS]
• Change in dorsolateral prefrontal event-related spectral perturbation (DLPFC ERSP) following iTBS [Time frame: baseline (pre iTBS), within one hour from iTBS]
• Change in dorsolateral prefrontal inter-trial coherence (DLPFC ITC) following iTBS [Time frame: baseline (pre iTBS), within one hour from iTBS]
• Change in AX-Continuous Performance Task Reaction Time (AX-CPT RT) following iTBS [Time frame: baseline (pre iTBS), within one hour from iTBS]
• Change in AX-Continuous Performance Task Error Rate (AX-CPT ER) following iTBS [Time frame: baseline (pre iTBS), within one hour from iTBS]
• Change in AX-Continuous Performance Task d' context (AX-CPT d') following iTBS [Time frame: baseline (pre iTBS), within one hour from iTBS]

Eligibility criteria

Inclusion criteria

• ages 18-40 years
• DSM diagnoses of Schizophrenia Spectrum Axis I disorders
• a duration of less than three years from beginning of psychosis, defined by report of symptoms and/or history of treatment, based on clinical guidelines employed in our UPMC psychoses clinics in Pittsburgh.

Exclusion criteria

• DSM intellectual developmental disorder
• significant head injury
• medical illness affecting brain structure or function
• significant neurologic disorder (e.g. seizure disorder)
• personal history or family history of epilepsy
• inability to provide informed consent
• concussion with loss of consciousness (LOC) greater than 10 minutes
• history of electroconvulsive therapy
• diabetes with associated seizures, loss of sensation/weakness in arms or legs, or momentary LOC
• pregnancy or postpartum (<6 weeks after delivery or miscarriage), as determined by self-report
• a psychotic illness with a temporal relation to substance use or head injury.
• current or past co-morbidity for alcohol or psychoactive substance dependence
• substance abuse, other than cannabis and/or alcohol, within the past one year

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Crossover

Masking

Quadruple blind

Primary purpose

Basic science

Study locations

United States · 1 center

• University of Pittsburgh — Pittsburgh

Identifiers

NCT: NCT05102929 · STUDY20050194 · 1R01MH125816-01A1

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗